Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada. -Positive preclinical data in...
SHIMENG Supply Chain Management Launches A-Share IPO, Largest External Shareholder Shoucheng Holdings (0697.HK) Sees Investment Value Enter Realization Phase
HONG KONG, Jan. 19, 2026 /PRNewswire/ -- SHIMENG SUPPLY CHAIN MANAGEMENT CO., LTD. ("SHIMENG"), an investee company of Shoucheng Holdings (0697.HK), has recently initiated its initial public offering (IPO) process on the Main Board of the Shenzhen...
BioDlink's Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion
BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil (a PIC/S member), Colombia, Egypt, Indonesia, and...